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ABSTRACT
Aim: To elicit patients’ preferences for HIV treatment of the rural population in Colombia.
Methods: A discrete choice experiment (DCE), conducted in a HIV clinic in Bogota, was used to exam-
ine the trade-off between five HIV treatment attributes: effect on life expectancy, effect on physical
activity, risk of moderate side-effects, accessibility to clinic, and economic costs to access controls.
Attributes selection was based on literature review, expert consultation and a focus group with six
patients. An efficient experimental design was used to define two versions of the questionnaire with
each of 12 choice sets and a dominance task was added to check reliability. A mixed logit model was
then used to analyse the data and sub-group analyses were conducted on the basis of age, gender,
education, and sexual preference.
Results: A total of 129 HIV patients were included for analysis. For all treatment attributes, significant
differences between at least two levels were observed, meaning that all attributes were significant pre-
dictors of choice. Patients valued the effect on physical activity (conditional relative importance of
27.5%) and the effect on life expectancy (26.0%) the most. Sub-group analyses regard age and educa-
tion showed significant differences: younger patients and high educated patients valued the effect on
physical activity the most important, whereas older patients mostly valued the effect on life expect-
ancy and low educated patients mostly valued the accessibility to clinic.
Limitations: One potential limitation is selection bias, as only patients from one HIV clinic were
reached. Additionally, questionnaires were partly administered in the waiting rooms, which potentially
led to noise in the data.
Conclusions: This study suggests that all HIV treatment characteristics included in this DCE were
important and that HIV patients from rural Colombia valued short-term efficacy (i.e. effect on physical
activity) and long-term efficacy (i.e. effect on life expectancy) the most.
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Human Immunodeficiency Virus (HIV), which infects the
immune system, continues to be responsible for a significant
disease burden. According to the World Health Organization
(WHO), 36.7 million people were infected with HIV world-
wide at the end of 20161. Of these HIV infected people, an
estimated 1.8 million people live in the Latin America region2
and 150,000 people live in Colombia1. In 2016, the HIV inci-
dence rate was estimated at 0.12 per 1,000 inhabitants in
Colombia, the prevalence rate was 0.25 per 1,000 inhabitants,
and there were 11,000 AIDS-related deaths2.
Over time, an HIV infection can result into a deadly dis-
ease: Acquired Immunodeficiency Syndrome (AIDS)3.
However, antiretroviral therapy (ART), which suppresses the
HIV virus and prevents transmission of the HIV virus, can pre-
vent this further progression of HIV/AIDS4. The WHO guide-
lines, which are in line with the HIV guidelines of the
Colombia Ministry of Health, recommends ART for all people
diagnosed with HIV, since it generally reduces the mortality
and morbidity rates and improves the quality-of-life of HIV
infected people5–7. It is paramount for individuals living with
HIV to adhere to the ART treatment, as these individuals
could live long and healthy lives5–7. This is in line with previ-
ous research that showed that Colombian HIV patients
receiving ART had relatively high health utilities8. Strict life-
long therapy adherence and optimal medication adherence
is needed to guarantee the treatment’s success9,10. Yet, a
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systematic review and meta-analysis on ART adherence
among adolescent and young adults aged 12–24, conducted
in 2014, indicated that in South America on average only
63% of the research population receiving ART is adherent to
therapy11. Enhancing patient adherence to HIV treatment is
therefore needed, since poor adherence is associated with
poorer treatment outcomes10.
Understanding patients’ preferences could provide rele-
vant insight to improve adherence to therapy. Matching
treatment elements to the needs of the target population
enhances adoption and sustained use of an intervention12,
such as antiviral therapy. Stated preference studies are
increasingly used to elicit patients’ preferences in health-
care13–15. Over the last years, several preference studies on
HIV treatment have been conducted in developed coun-
tries16–18, revealing the importance of efficacy of treatment
and quality-of-life for HIV patients. Likewise some preference
studies were conducted in developing countries, including
Tanzania19, Thailand20, South Africa21, and Colombia22. Only
the Colombian study specifically elicited patients’ preferences
for HIV/AIDS treatment. This study, which used a best–worst
scaling case 1 approach, ranked HIV treatment characteristics
and revealed that efficacy and prolonging life expectancy
were the most important characteristics for Colombian
HIV patients.
Colombia has a free and universal healthcare system,
meaning that there is free healthcare under the subsidized
system. However, little is known about the trade-offs that
Colombian HIV patients make between these important
treatment characteristics. Yet, trade-off information is useful
as it reflects the choice behaviour of patients regarding the
treatment profile. A discrete choice experiment (DCE) offers
the advantage to assess the relative importance of different
treatment characteristics that influence the patient’s choice23.
Promising results of the DCE technique can be found in aca-
demic literature13,14.
In addition, little is known about the treatment preferen-
ces of the rural population in developing countries such as
Colombia, since most of the previous DCEs assessed devel-
oped countries and/or urban settings13. In general, the rural
population and urban population differ, with on average
rural populations being lower educated24 and economically
disadvantaged compared to urban populations25. The trans-
ferability of preference studies in urban areas to rural areas
could be questioned26. Therefore, assessing the patients’
preferences of the rural population in particular and assess-
ing the differences in patients’ preferences between a rural
and urban setting may lead to new insights.
The aim of the present study is therefore to elicit patients’
preferences for HIV treatment in the rural population of
Colombia. Based on a previous best–worst scaling assessing
important HIV treatment characteristics in Colombia22, a DCE
was conducted to examine the trade-off between the most
important treatment characteristics and to examine if these
treatment preferences are influenced by patient characteris-
tics (e.g. age, gender, education, and sexual preference).
Findings of the DCE in the present study could potentially
contribute to clinical and policy decision-making where HIV
treatments are aligned to the preferences of Colombian HIV
patients. As matching treatment elements to user needs opti-
mizes the sustained use of an intervention12, the study find-
ings may in turn help enhancing adherence to therapy,
which ultimately may reduce AIDS-related morbidity and
mortality and optimize the quality-of-life of patients.
Methods
Discrete choice experiment
A DCE was used to elicit patients’ preferences for HIV treat-
ment of the rural population in Colombia. A DCE is a stated-
preference valuation technique to measure how people
value different attributes (e.g. effectiveness, costs, side-
effects) of a product or service (treatment, in this case)14,27.
The patients in the present DCE were asked to choose
between two hypothetical treatment options (i.e. Treatment
A vs Treatment B) that were described by means of five
treatment attributes and their associated levels. The assump-
tion is that participants would choose the option (i.e. the
attributes) with the highest expected utility. The present
study followed the user’s guide described by Lancsar and
Louviere14 and the ISPOR Good Research Practices for
Conjoint Analysis Task Force27.
Attributes and levels
The validity of a DCE depends on the accurate identification
and selection of the treatment attributes and their associated
levels28,29. We therefore followed a rigorous two-step process
to identify and select attributes and levels that were esti-
mated to be the most important treatment characteristics of
HIV patients in Colombia.
First, a literature review in PubMed was conducted to
examine which attributes were used in previous DCEs on
patients’ preferences in HIV treatment16–21,30. In addition, a
previous best–worst scaling study of Hendriks et al.22, which
identified the most important treatment characteristics of
HIV patients in Colombia, was used as the main basis for the
attributes of the present study. Then, two independent
researchers (AG and ES) blindly conducted a first selection.
They consulted which five attributes were preferred for inclu-
sion. In addition, a senior expert (MH) and a Colombian HIV
clinician (RC) were consulted until consensus was reached on
the first selection of the attributes. Subsequently, every attri-
bute was assigned with three associated levels. The selection
of levels was based on both existing literature and the know-
ledge of a Colombian HIV clinician (RC). The four researchers
(AG, ES, MH, and RC) consulted which levels should be
assigned until consensus was reached. An external validation
by a Colombian professor of Rosario (JG) was fur-
ther conducted.
In the second step, a focus group with six HIV patients of
Assistencia Cientifica de Alta Complejidad (ACAC), a HIV clinic
in Bogota Colombia, was held on April 2018. This focus
group aimed to gain information about which treatment bar-
riers and which side-effects were important to HIV patients
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and to evaluate the five attributes and levels. The focus
group confirmed that patients were concerned by treatment
outcomes, side-effects, and costs. As outcomes, the effect of
treatment on their life expectancy and on their daily physical
activity were deemed relevant to the patients, confirming
the first two attributes (effect on life expectancy, effect on
physical activity). Additionally, the risk of side-effects and
the accessibility to the clinic were relevant considerations
for the patients. The last attribute was, however, changed
after the focus group, i.e. the initially chosen attribute on fre-
quency of visits was replaced by a new attribute on eco-
nomic costs. Patients reported to be concerned by the
economic costs of their treatment, while the frequency of
visits was not deemed an important attribute. Finally, five
attributes were thus included in our DCE: effect on life
expectancy, effect on physical activity, risk of moderate side-
effects, accessibility to clinic, and economic costs to access
controls (i.e. travel costs). The complete list of the five attrib-
utes and their associated levels can be found in Table 1.
Experimental design and questionnaire
Since conducting a full factorial design (i.e. all possible treat-
ment combinations) would not have been feasible, a frac-
tional factorial design was chosen for the present study. This
means that the participating HIV patients were presented
with a sub-set of treatment profiles. This sub-set was
selected by using an efficient experimental design, which
uses a-priori information on parameters31. Ngene software
(version 1.1.1) was used to design 24 choice sets that were
blocked in two versions, 12 for version 1 and 12 for version
214,27. Attribute levels and their associated levels are pre-
sented as they are, as detailed in Table 1. Different colour
shading was used to distinguish the positive, neutral, and
negative levels. An example of a choice set can be found in
Figure 1.
The final questionnaire consisted of an introductory part
(with an overall introduction, informed consent, explanation
of each attribute, and example question), the main part (with
12 choice set questions and one dominance question) and
the additional part (with one question to rate the difficulty
on a 7-point Likert scale, six questions on socio-demographic
features, and three open questions on treatment barriers and
side-effects). In the dominance question, one treatment is
assumed to have better utility levels for all attributes (i.e.
higher positive effect on life expectancy and physical activity,
lower risk on side-effects, better accessibility and lower eco-
nomic costs to access the clinic) to test whether the
respondents correctly understood the questionnaire. The
questionnaire was offered offline and online. The online
questionnaire was designed by using Qualtrics software.
Initially, the questionnaire was developed in English by
two researchers (AG and ES). The final version of the English
questionnaire was approved on the content by a senior
expert (MH) and a Colombian HIV clinician (RC). Thereafter,
the questionnaire was translated into Spanish by a native
speaker and checked by a second native speaker (JG). Finally,
a pilot was held with six HIV patients. In response to this
pilot study, minor improvements were made.
Data collection and participants
The data collection process took place at ACAC, located in
Bogota (Colombia) in May 2018. Two researchers (AG and ES)
mainly collected the data; supported by several health pro-
fessionals of ACAC (e.g. two nurses filled in the offline paper
questionnaires with their patients, doctors promoted partici-
pation and/or sent patients to the researchers directly).
All patients with HIV (without restrictions) were included
in the analysis if they: (1) filled in the informed consent form,
(2) passed the dominance question, (3) filled in eight or
more choice set questions, and (4) were considered rural
(see description of rural patients below). Furthermore, a dis-
tinction was made between rural and urban patients based
on their place of residence and travel time. In the present
study, only the patients labelled as rural were included.
The inclusion criteria for rural patients were developed by
the two researchers (AG and ES) with help of a Colombian
HIV clinician (RC). The following inclusion criteria were used
for defining rural patients: patients that live outside Bogota
Table 1. The five attributes and their associated levels.
Attributes Levels
Effect on life expectancy Large positive effects: Live many years more
Moderate positive effects: Live a few more years
Mild positive effects: Live a short while more
(a few months, less than 2 years)
Effect on physical activity All physical activities without difficulty
Some physical activities with difficulty
All physical activities with difficulty
Risk of moderate
side-effects
1%: Low risk of side-effects
2.5%: Medium risk of side-effects
5%: Higher risk of side-effects
Accessibility to clinic Less than 2 hours
Between 2 and 5 hours




Low travel costs, paid by the patient
High travel costs, paid by the patient
Queson 1
Treatment A Treatment B









Risk of moderate side effects
5%: Higher risk of side
effects
2.5%: Medium risk of
side effects
Accessibility to clinic More than 5 hours Less than 2 hours
Economic costs to access controls High travel costs Subsidized travel costs
Which of the two treatments best
represent your preferences?
(Tick one box only)
Treatment A Treatment B
Figure 1. An example of a choice task in English.
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city, patients from Bogota that live in the localidad Usme
and Ciudad Bolıvar, patients from Bogota that live in selected
barrios of the localidad Suba, Usaquen and Bosa (see
Supplementary Material), and patients that live in barrios in
the outskirts of Bogota. If patients did not fill in the barrio,
then patients that live in the localidad Suba, Usaquen, and
Bosa were included. If patients did not fill in the barrio nor
the localidad, then a distinction was made based on their
travel time to the clinic. A cut-off point of 2 or more hours
of travel time was used as inclusion criteria. Patients that did
not fill in their place of residence or their travel time were
excluded. A map of Bogota with the included and excluded
barrios can be found in the Supplementary Material. This
study received ethical approval from ACAC and
Maastricht University.
Data analysis
In the present DCE, the treatment choices of patients were
observed in each choice set. These responses were analysed
using the random utility theory. The utility that a patient i
assigns to a treatment j (Vij) is modelled as the sum of two
parts: a systematic component based on the included attrib-
utes and an error component (ijt). In the present DCE, Vij is
specified as:
Vij ¼ b0 þ ðb1 þ g1iÞ  LARGEj þ ðb2 þ g2iÞ MODj
þðb3 þ g3iÞ WITHOUTj þ ðb4 þ g4iÞ
SOMEWITj þ ðb5 þ g5iÞ  SIDEEFj þ ðb6 þ g6iÞ  LESS2j
þðb7 þ g7iÞ  BET25j þ ðb8 þ g8iÞ
SUBSADj þ ðb9 þ g9iÞ LOWCOSTj
where b0 is the constant factor, b1–b9 are the main attribute
utility rates in the population, and g1i–g9i are error terms
capturing the individual variation in the attribute util-
ity values.
One attribute (risk of moderate side-effects) was treated
as a continuous variable, while the four other attributes
(effect on life expectancy, effect on physical activity, accessi-
bility to clinic, and economic costs to access controls) were
treated as categorical variables. For the categorical variables,
the regression model provided one coefficient for each level
with the exception of the reference level (mildly positive
effects, all physical activities with difficulty, more than 5 h,
and high travel costs). The reference level coefficients were
then calculated using the created coefficients of the other
levels of these attributes.
To describe these categorical variables (b1–b4 and b6–b9),
effect coding was used. Effect coding describes the different
levels by only using ones, zeros and minus ones. Effects cod-
ing was chosen over dummy coding of categorical variables,
as with dummy coding the parameter estimate for the base-
line (omitted) category cannot be recovered. Effects coding
has desirable properties in modelling conjoint-analysis data
and is widely used in many conjoint-analysis applications27.
When interpreting the analysis, the sign of the coefficients
indicates whether the level has a positive or negative effect
compared to the mean of the attribute. The magnitude of
the coefficients indicates the size of this effect. The param-
eter for the omitted category is the negative sum of the
included-category parameters and the 95% CI of the omitted
category was also based on the standard deviation and
covariance of the other levels27.
A mixed logit (MIXL) model (also named random param-
eter logit) was used to elicit patients’ preferences of HIV
treatment. Analyses were conducted using NLOGIT software
(Econometric Software, Inc., Plainview, NY), version 5.0. A
MIXL model has as advantage that it estimates the prefer-
ence heterogeneity by measuring a coefficient (i.e. degree of
preference) and a standard deviation of the coefficient per
parameter (i.e. degree of heterogeneity). All parameters were
drawn from a normal distribution and the estimation was
conducted using 1,000 Halton draws. The conditional relative
importance of the attributes was then estimated with the
magnitude of the coefficients using the range of the magni-
tude coefficients per attribute. Preferences estimate from the
model was then used to calculate the conditional relative
importance of attributes overall and per country. Using the
range method, the range of attribute-specific levels is calcu-
lated by measuring the difference between the highest and
lowest coefficient for the levels of the respective attribute.
The conditional relative importance is then calculated by
dividing the attribute-specific level range by the sum of all
attribute level ranges. The relative attribute importance cal-
culated with this method always depends on the range of
levels chosen per attribute and on the other attributes
included in the experiment.
The MIXL model identifies for which attributes there is a
significant preference variation. However, it does not provide
insight into why this variation exists. Therefore, additional
sub-group analyses were conducted to examine if the prefer-
ences differ among sub-groups in specific covariates (i.e. age,
gender, education, and sexual preference). Age was classified
according to patients with an age of 38 or younger and
patients older than 38, with 38 being the average age of the
study population. Gender was classified according to male
and female, with the category “other” being excluded.
Education was classified as either low educated (i.e. primary
and secondary school) and high educated (i.e. engineer and
university degree). Sexual preference was classified as hetero-
sexual or homosexual, with the categories “bisexual” and
“other” being excluded, due to the limited number of partici-
pants reflecting these categories. Each sub-group was first
conducted by a specific MIXL model. Then, to test significant
differences, a joint model using dummy variables was then
used to estimate significant differences in treatment prefer-
ences between sub-groups. The data analysed during the




The questionnaire was distributed among 405 HIV patients.
For the present study, 249 patients were excluded since they
were identified as urban and eight patients were excluded
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since they were unidentifiable due to the absence of demo-
graphic information. Of the remaining 148 rural patients,
19 patients were excluded due to failure of the dominance
question. A total of 129 questionnaires were thus included
for data analysis. An analysis including patients who failed
the dominance test provided very similar results.
Nearly two thirds (64%) of the patients were men, and
the mean age was 38.4 years. On average, patients graded
the difficulty of the questionnaire with a 3.6 on a 7-point
Likert scale (1 being extremely easy and 7 being extremely
difficult). The highest level of education of most patients was
secondary school (45%) and there was an almost equal distri-
bution of heterosexual preference (42%) and homosexual
preference (47%). The average travel time of the included
rural patients was almost two and a half hours (2:23) and
more than one third (36%) of the patients lived outside
Bogota. A more detailed overview of the patient characteris-
tics can be found in Table 2.
Patients preferences
The results of the MIXL model can be found in Table 3. A
total of 1510 (129 12 38) choices were made by the
patients. For all five treatment attributes, significant differen-
ces between at least two levels of the attribute were
observed. Patients valued most the effect on physical activity
(conditional relative importance score of 27.5%), followed by
the effect on life expectancy (26.0%). Furthermore, for acces-
sibility (22.1%), travelling less than 2 h or travelling between
2 and 5 h were significantly preferred compared to the
mean. As expected, patients had a negative preference for
an increase in risk of side-effects (16.7%). Of all five parame-
ters, the economic costs to access controls had the lowest
conditional relative importance (7.6%). There was no signifi-
cant preference for subsidized travel costs, a low preference
for low travel costs, and a negative preference for high
travel costs.
The standard deviation parameters, suggesting preference
variation among patients per level, were all significant except
for moderate positive effects on life expectancy and low
travel costs. The highest preference variation was found for
subsidized travel costs.
Sub-group analyses
Of the four sub-group analyses conducted (age, gender, edu-
cation, and sexual preference), only two sub-group analyses
(age and education) revealed a significant difference for at
least one attribute. An overview with the relative importance
of all attributes per patient (sub-) group is displayed in
Table 4 and the results of the two significant sub-group anal-
yses are further displayed in Tables 5 and 6.
Younger patients valued the effect on physical activity the
most, while older patients mostly valued the effect on life
expectancy. The sub-group analysis on education revealed
significant differences for all attributes. The conditional rela-
tive important attributes for low educated patients are, in
Table 2. Patient characteristics.
Characteristic Mean ± SD n¼ 129 %
Age (years) 38.4 ± 12.4
Difficulty (7 Likert scale) 3.6 ± 1.7






Primary school 23 18.9
Secondary school 55 45.1
Engineer degree (technologist) 32 26.2







Bogota (rural) 82 63.5
Outside Bogota 47 36.4
Abbreviation. SD, standard deviation.
Table 3. Results of the random parameter logit model.
Attributes and levels Coefficient 95% CI SD 95% CI Relative importance
Life expectancy (effect) 26.0%
Large positive effects 0.45 (0.29, 0.61) 0.34 (0.17, 0.51)
Moderate positive effects 0.05 (0.06, 0.16) 0.01 (0.48, 0.51)
Mild positive effects (Ref) 0.50 (0.35, 0.66)
Physical activity (effect) 27.5%
All without difficulty 0.53 (0.39, 0.68) 0.33 (0.15, 0.50)
Some with difficulty 0.06 (0.17, 0.05) 0.27 (0.09, 0.44)
All with difficulty (Ref) 0.47 (0.31, 0.63)
Risk of side-effects 16.7%
1% increase in risk 0.15 (0.23, 0.08) 0.13 (0.02, 0.24)
Accessibility (to clinic) 22.1%
Less than 2 hours 0.31 (0.18, 0.43) 0.27 (0.09, 0.45)
Between 2 and 5 hours 0.20 (0.08, 0.31) 0.27 (0.10, 0.45)
More than 5 hours (Ref) 0.50 (0.36, 0.65)
Economic costs (access) 7.6%
Subsidized travel costs 0.09 (0.06, 0.24) 0.48 (0.31, 0.64)
Low travel costs 0.10 (0.01, 0.20) 0.14 (0.20, 0.48)
High travel costs (Ref) 0.18 (0.02, 0.35)
Abbreviations. CI, confidence interval; SD, standard deviation.
SD values correspond to the random component of the model coefficients. Number of observations ¼ 1,548; Pseudo R-squared ¼ 0.082;
Log likelihood ¼ –960.57; Akaike information criterion ¼ 1.29.p< .01, p< .05, p< .1.
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descending order, accessibility, physical activity, life expect-
ancy, travel costs, and side-effects. However, high educated
patients had a different descending order of relative
importance, namely: physical activity, life expectancy, side-
effects, accessibility, and travel costs.
Discussion
This study elicited patients’ preferences for HIV treatment of
the rural population in Colombia. It is important to under-
stand the preferences of specific populations as needs may
vary across groups. Even the disproportionately affected by
HIV may be less likely to take antiretroviral therapies32.
Understanding the patients’ preferences for HIV treatment
could contribute to better health communication to enhance
the uptake of treatment. For all treatment attributes included
in this study, significant differences between at least two lev-
els were observed, meaning that all attributes were signifi-
cant predictors of choice behaviour and could therefore be
considered as important for HIV treatment. HIV patients val-
ued a treatment with effect on physical activities without dif-
ficulty, with a mild positive effect on life expectancy, with
accessibility of less than 2 h, with a low risk of side-effects,
and with subsidized travel costs. The findings indicate that,
based on the conditional relative importance, patients find
treatment effects (i.e. short-term (physical activity) and long-
term (life expectancy)) the most important attributes.
These findings are in line with a previous best–worst scal-
ing that was conducted in Colombia and revealed that effi-
cacy and prolonging life expectancy were the most
important attributes22. Our study, using a DCE, offers the
advantage to assess the trade-offs between the most import-
ant attributes. Furthermore, previous DCEs have investigated
patients’ preferences in HIV treatment in Europe16–18. These
studies also showed that efficacy and quality-of-life are
important attributes for HIV patients.
The sub-group analysis revealed that older patients mostly
valued the effect on life expectancy, while younger patients
preferred the effect on physical activity over all other
Table 5. Results of sub-group analyses for age.
Attributes and levels Patients aged 38 Patients aged >38 p-value
Coefficient SD Coefficient SD
Life expectancy (effect)
Large positive effects 0.39 0.33 0.54 0.37 .77
Moderate positive effects 0.10 0.01 0.00 0.25 .38
Mild positive effects (Ref) 0.49 0.54
Physical activity (effect)
All without difficulty 0.68 0.21 0.36 0.39 .00
Some with difficulty 0.08 0.35 0.02 0.02 .58
All with difficulty (Ref) 0.60 0.34
Risk of side-effects
1% increase in risk 0.20 0.07 0.09 0.24 .11
Accessibility (to clinic)
Less than 2 hours 0.32 0.11 0.28 0.45 .44
Between 2 and 5 hours 0.19 0.23 0.14 0.20 .68
More than 5 hours (Ref) 0.51 0.42
Economic costs (access)
Subsidized travel costs 0.09 0.23 0.08 0.72 .90
Low travel costs 0.11 0.19 0.12 0.08 .90
High travel costs (Ref) 0.20 0.20
Abbreviations. CI, confidence interval; SD, standard deviation.
SD values correspond to the random component of the model coefficients.
Number of observations ¼ 780 (38) and 708 (>38); Pseudo R-squared ¼
0.092 (38) and 0.106 (>38); Log likelihood ¼ –484 (38) and –423 (>38);
Akaike information criterion ¼ 1.31 (38) and 1.29 (>38).p< .01, p< .05, p< .1.
Table 4. The relative importance of HIV treatment attributes per patient
sub-group.









Life expectancy (effect) 26.0 19.6 34.2 25.1 28.5
Physical activity (effect) 27.5 32.2 22.2 24.1 30.7
Risk of side-effects 16.7 20.1 11.4 10.7 20.4
Accessibility (to clinic) 22.1 20.9 22.2 28.1 13.4
Economic costs (access) 7.6 7.3 10.1 12.0 7.0
Table 6. Results of sub-group analyses for education.
Attributes and levels Low educated patients High educated patients p-value
Coefficient SD Coefficient SD
Life expectancy (effect)
Large positive effects 0.35 0.15 0.99 0.54 .03
Moderate positive effects 0.03 0.18 0.08 0.04 .50
Mild positive effects (Ref) 0.40 1.07
Physical activity (effect)
All without difficulty 0.40 0.04 1.05 0.86 .01
Some with difficulty 0.08 0.23 0.07 0.51 .36
All with difficulty (Ref) 0.32 1.12
Risk of side-effects
1% increase in risk 0.08 0.00 0.37 0.40 .02
Accessibility (to clinic)
Less than 2 hours 0.36 0.25 0.23 0.52 .23
Between 2 and 5 hours 0.12 0.37 0.37 0.00 .13
More than 5 hours (Ref) 0.48 0.60
Economic costs (access)
Subsidized travel costs 0.17 0.49 0.15 0.01 .11
Low travel costs 0.02 0.27 0.36 0.04 .03
High travel costs (Ref) 0.19 0.21
Abbreviations. CI, confidence interval; SD, standard deviation.
SD values correspond to the random component of the model coefficients. Number of observations ¼ 936 (LowE) and 528
(HighE); Pseudo R-squared ¼ 0.072 (LowE) and 0.211 (HighE); Log likelihood ¼ –585 (LowE) and –283 (HighE); Akaike informa-
tion criterion ¼ 1.33 (LowE) and 1.16 (HighE).p< .01, p< .05, p< .1.
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attributes. This difference could be explained by the fact that
older patients have, compared with younger patients, a
higher change of mortality, which could explain the import-
ance of effect on life expectancy. Younger and older patients
are in different stages of life. Younger patients might worry
about their study, job and/or taking care of their family and
not so much about their life expectancy, since this could be
seen as a concern for later. In contrast, older patients might
worry more about their health, quality-of-life, and life expect-
ancy, since these issues shifted from being a long-term con-
cern to a short-term concern.
Moreover, the sub-group analyses revealed some differen-
ces between low and high educated patients. High-educated
patients valued efficacy (on life expectancy and physical
activity) higher than low educated patients. This difference
could be explained by the link between the education
degree and the knowledge on HIV/AIDS (i.e. the course, the
severity, and the seriousness) and the treatment effects. It is
expected that low educated patients have less knowledge. In
addition, the present study revealed that low educated
patients valued accessibility and costs higher than high edu-
cated patients. This difference could be explained by the
expectation that low educated patients have a lower income
compared to high educated patients. Low educated patients
could therefore find accessibility and costs more important
attributes, since long travel distance and high travel costs
come with an increase in expenses.
Furthermore, a similar DCE study conducted in the urban
population of Bogota showed similar results33. Both urban
and rural populations deemed the attributes “effect on phys-
ical activity” and “effects on life expectancy” as most import-
ant. The sub-group analysis showed that in both
populations, higher educated patients preferred large effects
with regards to life expectancy and deemed travel costs as
less important, compared to lower educated patients.
Findings are thus in line with prior expectations and DCE lit-
erature, which hints at transferability of results to a
Colombian urban population of HIV patients. However, with
regards to physical activity, this attribute was especially
deemed important to the higher educated sub-group in the
rural population. For physical activity, no differences were
found regards the educational groups in the urban popula-
tion. Further research, using qualitative methods, may shed
light on this mechanism.
This study provides one of the first preference studies for
HIV treatment in developing countries, especially in a rural
population. Patients’ preferences are nowadays increasingly
conducted and can provide relevant insights for policy and
clinical decision-making. Preference research is nowadays
increasingly used in policy decision-making and may help to
develop and assess healthcare interventions. Our study
revealed that HIV treatment benefits (i.e. effect on physical
activity and the effect on life expectancy), risks, but also
costs and the access to the clinics are important for patients.
Optimizing these treatment characteristics could lead to opti-
mizing treatment adherence. This is especially important as
research has shown that adherence to ART prolongs and
improves the lives of HIV patients34,35, which has a positive
effect on the health status, efficiency of care, productivity,
and economy of the society in question.
Strengths and limitations
This study has several strengths and limitations. First, this
study used a focus group with HIV patients to evaluate the
chosen attributes and levels, a pilot study with HIV patients
to evaluate the Spanish questionnaire, and a dominance
question to examine if the patients understood the question-
naire. Patients that failed the dominance question were
excluded for the present study. Furthermore, two versions
were used to increase the validity and statistical efficiency of
the present study. Second, at all times there were two
researchers present during the data collection. They ensured
that patients were correctly instructed and that questions
were answered. This guidance increases the likelihood that
the questionnaire is correctly understood and completed.
However, this study also has limitations. First, selection
bias could have occurred. The questionnaire only reached
rural patients that visited the HIV clinic. In addition, some
patients were unable to participate due to illiteracy or blind-
ness. This leads to an increased likelihood of sampling bias,
also referred to as sample selection bias. Therefore, more
research on rural patients who do not visit the HIV clinic is
needed. Second, data collection was conducted in only one
clinic in Bogota. The generalizability to the entire population
of Colombia could be questioned. Therefore, more research
in other areas of Colombia is needed. Third, the sample size
is relatively small, which could have hindered the statistical
power of the study. Yet, although there are guidelines
regarding sample size requirements for stated choice data,
the minimum sample size in terms of the statistical power is
not straight forward, which depends, for instance, on the
specific hypotheses tested36. Despite the sample size not
being large, this study still yielded sufficient power to illus-
trate significant results. Fourth, there is an ambiguous elem-
ent to the attribute levels, such as “large” and “moderate”,
which may reflect different meanings for different individu-
als. Additionally, as attributes were presented as they are
without providing an elaborate description per attribute, a
potential limitation is that attributes were interpreted differ-
ently across participants. Fifth, although significant differen-
ces were identified in the sub-group analyses, reflecting real
differences between groups, the lack of difference between
other sub-group pairs could be due to a lack of power as
the sample size is small. Sixth, the data collection circum-
stances were not optimal. The data collection was partly exe-
cuted in the waiting room (which sometimes was noisy) or
patients were distracted because they had to go to their
appointment. Last, future research could elaborate more in-
depth on HIV patient preferences in Colombia (e.g. examin-
ing patients’ preferences of rural HIV patients that are not
visiting a HIV clinic), could examine the transferability of HIV
patient preferences to HIV patients in other (Latin American)
countries, and could examine the transferability of the prefer-
ences of HIV patients to the preferences of patients having
another disease than HIV.
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In conclusion, to the best of our knowledge, this is the
first study to elicit patient preferences for HIV treatment of
the rural population of Colombia. The present study revealed
that all attributes included in this DCE were important for
HIV patients. Based on the conditional relative importance,
the effect on physical activity and the effect on life expect-
ancy were the most valued attributes.
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